Key Points
In terms of the drug’s own half-life and duration of effect, nifedipine (Adalat) has the fastest onset and shortest half-life, felodipine (Plendil) follows, and amlodipine (Norvasc) has the longest duration and slowest onset.
Original Text
This article is converted by SimpRead, original source mp.weixin.qq.com
- For medical professionals’ reference only
How to differentiate among these 3 commonly used “dipines”?
Calcium channel blockers (CCBs) are first-line drugs for hypertension treatment with many types. Even within the same class, each drug differs in pharmacokinetics and clinical effects — “harmonious yet distinct, each with pros and cons.”
Recently, Jiexiaoyao received questions from readers.
Always eager to respond, Jiexiaoyao quickly arranged this — today let’s take a look at the differences among the 3 common “dipines”: felodipine, nifedipine, and amlodipine.
1
“Sprint, middle distance and marathon” — large differences in pharmacokinetics
Considering only the half-life and duration of drug effect, nifedipine has the fastest onset and shortest half-life, felodipine next, and amlodipine has the longest duration and slowest onset.
Table 1 Pharmacokinetic properties of nifedipine, felodipine, and amlodipine [1]
Note: This table is compiled from “Drug Comparisons and Rational Clinical Choice - Cardiovascular Diseases Volume,” published by People’s Medical Publishing House. Differences may exist due to different manufacturers or formulations and are for reference only.
2
Common dosage forms “each has its own style,” usage and dosage need attention
Besides the pharmacokinetic characteristics of the drugs themselves, the drug formulation is also a key factor affecting efficacy.
▎ Nifedipine: Immediate-release tablets, sustained-release tablets, controlled-release tablets
Nifedipine immediate-release tablets are short-acting antihypertensives, and are currently not used for long-term blood pressure control. However, pharmaceutical technology allows nifedipine to be formulated as sustained-release and controlled-release tablets, effectively slowing and prolonging its onset and effect.
Nifedipine sustained-release tablets are taken twice daily; controlled-release tablets are taken once daily.
Among them, nifedipine controlled-release tablets have a non-absorbable shell; after the tablet slowly releases and absorbs inside the body, intact empty shells can be found in feces.
▎ Felodipine: Immediate-release tablets, sustained-release tablets (capsules)
Felodipine immediate-release tablets are taken twice daily. Felodipine sustained-release tablets are taken once daily and should not be crushed, broken, or chewed.
Felodipine bioavailability is significantly affected by food; when given with high-fat or carbohydrate meals, peak concentrations can increase by 60%. Felodipine sustained-release tablets are preferably taken on an empty stomach in the morning.
▎ Amlodipine: Immediate-release tablets
Amlodipine is a long-acting drug with a metabolic half-life over 30 hours, taken once daily. It can be taken before or after meals and is not limited to morning administration.
3
“Networking” differs, remember drug interactions
The liver enzyme CYP3A4 inducers and inhibitors have a significant impact on CCB drugs, with many drug interactions.
In addition, pay special attention to:
■ Amlodipine can increase blood concentrations of simvastatin, so when used together, the maximum dose of simvastatin is 20 mg/day.
■ Cimetidine can inhibit the metabolism of felodipine and nifedipine, increasing felodipine peak concentration and bioavailability by approximately 55%, and increasing nifedipine bioavailability by 77%–99%.
■ Among foods, grapefruit should be noted. Grapefruit juice has the most noticeable effect on felodipine and nifedipine.
Studies have found that: co-administration of felodipine and grapefruit juice can increase felodipine blood concentration by about twofold;
co-administration of nifedipine and grapefruit juice not only increases blood concentration but also prolongs drug effect duration;
co-administration of amlodipine and grapefruit juice has no obvious effect.
4
“Targeted treatment” is important, comparison of antihypertensive characteristics [2]
Nifedipine
Advantages: Controlled-release tablets have small plasma concentration fluctuations with peak-to-trough ratio close to 1. Compared with amlodipine, nifedipine controlled-release tablets control blood pressure faster, usually achieving optimal antihypertensive effect in 3-5 days.
Disadvantages: Immediate-release tablets cause blood pressure reduction too rapidly, easily stimulating the sympathetic nervous system, causing adverse reactions; effect duration is short, blood pressure reduction unstable, with significant fluctuations.
Recommendations: For patients with severe hypertension requiring rapid blood pressure reduction, nifedipine controlled-release tablets are more suitable than long-acting drugs like amlodipine.
Felodipine
Advantages: Onset is faster than amlodipine, allowing blood pressure to quickly reach steady state. Felodipine has much greater selectivity for blood vessels than for the heart, so while reducing blood pressure effectively, it has minimal cardiac effects.
Disadvantages: Due to a shorter half-life than amlodipine, felodipine is slightly less effective in controlling nighttime and early morning hypertension.
Recommendations: Suitable for patients with mild to moderate hypertension. Research on felodipine in severe hypertension is relatively limited.
Amlodipine
Advantages: Very long half-life, once daily dosing, very convenient. Effect is stable, tablets can be divided, drugs accumulate in the body; occasionally missing a dose has little impact.
Disadvantages: Onset is slower; initial antihypertensive effect may be minimal, generally taking 1-2 weeks to lower blood pressure, and 6-8 weeks to reach maximum effect.
Recommendations: For patients with poor compliance or prone to missing doses, amlodipine with its relatively long half-life is preferred.
5
CCB “common drawback,” impact on heart failure [3]
All CCBs inhibit myocardial contractility, but studies find nifedipine has stronger myocardial contractility inhibition, which may worsen heart failure symptoms;
Felodipine’s peripheral vascular selectivity relative to the heart is significantly higher (118:1), so risk of worsening heart failure symptoms is lower;
Amlodipine is neutral in heart failure patients and unlikely to exacerbate heart failure symptoms.
6
“Specialist use,” note differences for special populations
-
Pregnant patients: Nifedipine controlled-release tablets can be used, while amlodipine and felodipine have not been evaluated for safety and efficacy, generally not recommended;
-
Children: Amlodipine’s instructions mention its use in children aged 6 to 17 with hypertension, whereas nifedipine and felodipine lack pediatric usage records and safety data;
-
Liver impairment patients: Use of felodipine is not recommended in hepatic insufficiency; amlodipine dose escalation should be slow in severe hepatic impairment; nifedipine use in hepatic impairment requires strict monitoring and dosage reduction if conditions are severe;
-
Renal impairment: Amlodipine, felodipine, and nifedipine generally do not require dosage adjustment;
-
Heart failure patients [4]: For patients with blood pressure still >130/80 mmHg after antihypertensive therapy (diuretics, ACEI/ARB, β-blockers, aldosterone receptor antagonists), addition of amlodipine or felodipine is recommended. For stable angina combined with heart failure, when long-acting CCB is necessary, amlodipine or felodipine is recommended.
Did you gain anything after reading this article? Feel free to share it for more people to see!
If you want differentiation of other drugs, feel free to leave comments~
References:
[1] Tong Rongsheng et al. Drug Comparisons and Rational Clinical Choice - Cardiovascular Diseases Volume [M]. Beijing: People’s Medical Publishing House, 2013: 34-41
[2] Zeng Chunmei. Clinical application of dihydropyridine calcium channel blockers in hypertension [J]. Contemporary Medicine, 2017, 23(18):3.
Chinese Medical Association Cardiovascular Branch Heart Failure Group, Chinese Medical Doctor Association Heart Failure Professional Committee,
[3] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC [J]. Eur Heart J, 2012, 33(14):1787-847.
[4] Editorial Board of Chinese Journal of Cardiovascular Diseases. Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2018 [J]. Chinese Journal of Heart Failure and Cardiomyopathy (Bilingual), 2018, 2(4):30.
First published by Medical Community Clinical Pharmacy Channel
Author: Shi Chunhuan
Editor: Xiao Dangdang
More excellent clinical medication articles
Follow the Clinical Pharmacy Channel to view
The Medical Community strives for accuracy and reliability of published content at the time of approval, but does not guarantee timeliness or completeness of the content or cited materials (if any), nor accept responsibility for any consequences resulting from outdated or inaccurate content. Relevant parties are advised to verify when using this content for decision-making.
